Research

Hormonal

Tirzepatide is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) compared to placebo, insulin, and GLP-1 RAs, particularly at higher doses.

Expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but often improve over time. Discuss management strategies with your doctor.

StrongQualifiesHIGH confidence
The incidence of gastrointestinal adverse events, including nausea, vomiting, diarrhea, and decreased appetite, was significantly higher at all doses of tirzepatide compared to placebo... When compared with GLP-1 RAs, higher doses of tirzepatide were associated with increased risk of nausea, diarrhea, and decreased appetite, but not vomiting.
Ligang Liu et al. · Pharmaceuticals · 2025

Why this rating

Meta-analysis of 14 RCTs.

Source

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials

Ligang Liu et al. · Pharmaceuticals · 2025

DOI 10.3390/ph18050668

Meta-analysis · 14 studiesCited 15×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →